The antiviral and cytotoxic effects of ara-arahinoside monophosphate, 2',3', dideoxy-cytidine, ganciclovir, 9-2(-phosphonyhnethoxyethyl) adenine, 2',3'dideoxy3'-thiacytidine and recombinant interferon-alpha were studied using two human hepatitis B virus transfected hepatoma cell lines, HepGZ 2.2.15 and HB 611. After 9 days of exposure, starting on day 3 after seeding, inhibition of extracellular HBV-DNA expressed as IDss was in the 0.1-1.0 /cM range for 2',3'-dideoxy3'-thiacytidine and 9-Z(-phosphonyhuethoxyethyl) adenine and >lO PM for dideoxy-cytidine, araarabinoside monophosphate and ganciclovir in both cell lines At 2.500 U/ml recombinant interferon-alpha showed less than 20% inhibition in both cell lines. The HBV-DNA inhibitory effects of 2',3'dideoxy-3'-thiacytidine and 9-2(-phosphonyhnethoxyethyl) adenine were also investigated after 1 and 3 days of exposure. In that setting IDsa's were 10 and 3.3 PM for 2',3'-dideoxy-3'-thiacytidine and >lOO and 30 PM for 9-2(-phosphonyhuethoxyethyl) adenine, respectively. No major inhibitory effect on hepatitis B surface antigen and hepatitis B e antigen secretion was observed for any agent in this study, except for 9-Z(-phosphonylmethoxyethyl) adenine in HB 611 cells. Cytotoxicity ESEARCH R on hepatitis B virus has been hampered by the absence of an in vitro cell culture system for hepatitis B infection. Infection of hepatitis B virus in primary cultures of human hepatocytes has been reported, but great variability has been observed in levels of HBV replication (1).
R
on hepatitis B virus has been hampered by the absence of an in vitro cell culture system for hepatitis B infection. Infection of hepatitis B virus in primary cultures of human hepatocytes has been reported, but great variability has been observed in levels of HBV replication (1) .
As an alternative, transfection of various hepatoma cell lines with hepatitis B virus DNA has been introduced. Stable transfection was established for the HepG2 2.2.15 and the HB 611 cell lines. Both cell lines excrete hepatitis B surface antigen, hepatitis B e antigen and complete Dane particles (2, 3) . These two cell lines are now widely used as model systems for screening of antiviral agents with activity against HBV In previous studies various experimental designs were described to assess the therapeutic effect of antiviral agents. Differences in time of start of exposure of cells to the agents, duration of exposure, cell system, time lapse between exposure and measurement of anti-HBV effect and different types of cytotoxicity tests may ultimately have influenced the results. Therefore, it is of interest to investigate the two commonly used HBVproducing cell lines, the HepG2 2.2.15 and the HB 611 cells, simultaneously For comparison of the feasibility of these cell lines, we have chosen antiviral agents with different inhibitory properties: ara-arabinoside monophosphate (Ara-AMP) (4) and ganciclovir (DHPG) as suspected DNA polymerase inhibitors (non-reactive in growth inhibit.ion of retroviruses: J. Bazarini, personal communication); 9-2 (-phosphonylmethoxyethyl) adenine (PMEA) as inhibitor of DNA polymerase as well as reverse transcriptase (5), and dideoxy-cytidine (ddC) and 2'-3'-dideoxy-3'-thiacytidine (Lamivudine) as reverse transcriptase inhibitors (6, 7) . Recombinant interferon-a (IFN-a) is a presumed inhibitor of the viral RNA and protein synthesis (8, 9) . It is very important to establish the effects of drug activity on cytotoxicity and the effect of cytotoxicity on the evaluation of the antiviral effect in the earliest phase of selection of new drugs. For this reason we investigated the time and duration of treatment in relation to antiviral effect and cytotoxicity.
Material and Methods

Antiviral agents
Ara-arabinoside monophosphate and 2'3'-dideoxy cytidine were purchased from Sigma Chemical Co. (St Louis, USA). Ganciclovir was purchased from Sarva Syntex Corporation (Palo Alto, USA). Recombinant interferon-a was a gift from the Schering Plough Corporation (Kenilworth, NY, USA). 9-2-(phosphonylmethoxyethyl) adenine was a gift from Dr. J. Balzarini (Rega Institute of the Catholic University, Leuven, Belgium). Lamivudine is the negative enantiomer of 2',3'-dideoxy-3'-thiacytidine and was a gift from Glaxo Research and Development (Greenford, UK).
Human hepatoma cell lines
The HepG2 2.2.15 hepatoblastoma cell line was kindly donated by Dr. G. Acs (Mount Sinai Medical Center, New York, NY, USA); the HB 611 cell line was a gift from Dr. K. Matsubara (Institute of Molecular and Cellular Biology, Osaka, Japan).
Cells were seeded onto 25 cm2 tissue culture flasks (Costar) at a density of 4~ lo4 cells/cm2 in Dulbecco's modification of Eagle's medium (DMEM), supplemented with 2 mmol/l L-glutamine (Flow Laboratories), garamycine (40 &ml), amphotericin B (2.5 pg/ ml), the neomycin analogue G418 (360 &ml for HepG2 2.2.15 cells; 200 &ml for HB 611 cells) and 10% fetal bovine serum (FBS, Hyclone Laboratories Inc). When cells had reached confluence (day 6), FBS was reduced to 2%. Cell cultures were maintained in 5% CO2 atmosphere at 37°C.
All antiviral agents were investigated for their anti-HBV effects after continuous exposure of the cells to these drugs for 9 days. Initially, tenfold dilution steps were used. Intermediate dilution steps were chosen for the final experiments to obtain drug levels closer to the expected 50% inhibitory concentration. In these experiments exposure of the cells to the drug started on day 3 by replacing the culture medium with culture medium supplemented with the antiviral agent. This was repeated on day 6 and 9.
In short-term exposure experiments, medium was also replaced on day 3 by culture medium containing the antiviral agent. Exposure of the cells to the drug ended after, respectively, 1 and 3 days. Medium without antiviral agent was changed on day 6 and 9.
Cell culture supernatants from continuous (9 days) and short-(1 day and 3 days)-term exposures were harvested on day 12 for HBV-DNA extraction.
Analysis of HBV-DNA
For analysis of extracellular HBV-DNA the cell culture supernatant was clarified by centrifugation at 1000 g for 10 min. Aliquots were stored at -20°C until further analysis. After concentration by polyethylene glycol (PEG, 10% w/v) precipitation, the pellets were resuspended in a buffer consisting of 10 mM Tris-HCl pH 8.2, 400 mM NaCl, 2 mM Na2EDTA, 0.6 mg/ml proteinase K and 1% SDS and incubated overnight at 45°C. Total HBV-DNA was extracted with phenol, followed by extraction with phenol:chloroform:isoamyl alcohol (25:24: 1) and chloroform:isoamyl alcohol (24:l). The DNA was precipitated overnight in ethanol. After two washes with ethanol 70%, the DNA pellets were dissolved in TE (10 mM Tris-HCl pH 7.5, 2 mM Na2EDTA) in 10% of the starting volume.
For dot blot analysis, extracted DNA was applied to a Hybond N+ membrane (Amersham Life Science Products) in the Convertible Filtration Manifold System (BRL, Life Technologies Inc.) as described previously (10) . Three reference samples were included in any hybridization run for quality and sensitivity control.
Hybridization of HBV-DNA sequences was performed with a [32P]dCTP labelled EcoRl fragment of pCPl0 containing the full length 3.2 kb genome of HBV All labelling reactions were carried out with the Prime-a-Gene Labelling System (Promega). HBV-DNA was visualized by autoradiography. The limit of detection was 0.1 pg HBV-DNA.
The intensity of the autoradiographic dot spots was quantitated by scanning in an LKB 222-020 Ultra Scan XL laser densitometer. The 50% inhibitory dose (ID& was defined as the drug concentration that reduced the level of HBV-DNA in the culture medium by 50%. The IDs0 values were obtained by plotting percentage inhibition compared with control (no drug) versus the drug concentration. The IDso could be determined with a 15% coefficient of variation.
Cytotoxicity
The 50% cytotoxic dose (CDs,,) was determined by inhibition of [3H-methyl]deoxythymidine ([3H-methyl] dThd) incorporation and measured after 24 h of incubation at respectively 3 and 12 days after seeding (11) .
The Therapeutic Index (TI) is the ratio of CDS0 over ID5o.
Extracellular HBsAg and HBeAg analysis
HBsAg and HBeAg secretion in clarified tissue culture medium were analyzed on day 12. HBsAg and HBeAg were determined semi-quantitatively by end-point titration in radioimmunoassays (AUSRIA II and HBe rDNA, Abbott Laboratories, Chicago, Ill., USA). 
Results
Anti-HBV effect
Inhibition of extra-cellular HBsAg and HBeAg
HBsAg and HBeAg secretion from both HepG2 2.2.15 and HB 611 cell cultures were not inhibited for the antiviral agents under study except for PMEA, which inhibited HBsAg secretion in HB 611 cell cultures. A reproducible 50% inhibition was found at 30 PM. Table 1 also shows CDS0 results in the two hepatoma cell lines. On day 4 the order of CDs0 was similar for HepG2 2.2.15 and HB 611, with the highest level of CDS0 for Lamivudine and lowest for Ara-AMP Comparing day 4 with day 12, lower levels (7-100 fold) of CD50 were observed on day 12 for Lamivudine, PMEA, ddC and DHPG, but not for Ara-AMP The most dramatic change was noticed for ddC in HepG2 2.2.15 cells. In contrast to the results on day 4, the level of CD50 on day 12 suggests that the antiviral activity on day 12 may be strongly influenced by cytotoxicity. This change steeply affected the therapeutic index of the drug (Table 1) . Fig. 1 illustrates that for PMEA and Lamivudine the concentration ranges of inhibitory activity and cytotoxicity are clearly separated. These two agents were studied for post-exposure inhibitory properties after short-term exposure in HepG2 2. After 3 days of exposure to PMEA and Lamivudine, the IDso was 30 ,YM and 3.3 PM, respectively, compared to 1.2 and 0.02 PM, after 9 days of exposure. In the l-day exposure experiment PMEA and Lamivudine had IDSo's of >lOO and 10 PM, respectively
Cytotoxicity
Short treatment with PMEA and Lamivudine
Discussion
This is the first report on simultaneous investigation of antiviral agents in the two HBV-transfected hepatoma cell lines HepG2 2.2.15 and HB 611. The HBV inhibitory and cytotoxic effects of the agents under study were very similar for the two hepatoma cell lines after continuous exposure for 9 days. The order of effectiveness based on inhibition of extracellular HBV-DNA for both HepG2. In most studies on HBV inhibitory agents, cytotoxicity in cell culture systems was measured in lymphoblastoid or hepatoma cell cultures early after plating of the cells. At that time cellular DNA synthesis is expected to be highest. Antiviral activity, measured as inhibition of the level of HBV-DNA under continuous exposure to the drug is, in fact, because of the need to change the culture medium every 3 days, determined at the end of the treatment period. Therefore, we included in our study cytotoxicity measurements on day 12 in addition to the usual measurement of cytotoxicity at the start of treatment (day 4). For both cell lines we observed an increase in cytotoxicity for Lamivudine, PMEA, ddC and DHPG after prolonged drug treatment. The increase in cytotoxicity as measured by [3H-methyl] dThd incorporation was confirmed by cell death in dye fixing experiments (results not shown).
The most dramatic change in CD50 upon time of evaluation was measured for ddC in HepG2 2.2.15 cells. An unfavourable cytotoxic aspect of ddC was also apparent in inhibitory measurements of mitochondrial DNA (12, 13) . In clinical trials peripheral neuropathy was observed at all doses (18-20). Our experiments suggest that the elevated cytotoxicity of ddC on day 12 may result in an overestimation of the inhibitory effect on the level of HBV-DNA and a too favourable therapeutic index for this drug.
Reduction of HBsAg concomitant with HBVDNA in the culture medium could not be explained by accumulation within a subcellular fraction, since with increasing drug concentration both intra-, and extracellular levels of HBV-DNA decreased quite similarly.
Compared to the other agents in our study, Lamivudine is the most vigorous antiviral agent, with low toxicity on day 4 as well as day 12. Our in vitro findings with Lamivudine in these two cell lines were confirmed in pilot studies with Lamivudine in chronic hepatitis B patients (21). Furthermore, the outcome of our short exposure experiments are of interest for intermittent administration of antiviral drugs to reduce or avoid delayed toxic effects in man.
In summary, with the limited number of agents in this study we conclude that HepG2 2.2.15 cells are more suitable than HB 611 because of higher virus yields and better culturing characteristics, with a similar inhibitory effect on Dane particle secretion.
The high yields of HBV from the HepG2 2.2.15 cells made it possible to use a 24-well tissue culture system (results not shown) and to perform direct analysis of extra-cellular HBV-DNA in cell-culture medium without PEG concentration and DNA extraction or PCR capturing (22) .
Measuring cytotoxicity at the end of the incubation period may have a further discriminatory effect on the calculated and often overestimated therapeutic index. The severe toxicity observed in the FIAU study stresses once more the need for sensitive laboratory methods to predict toxic effects in man. Cell culture systems like HBV-producing hepatoma cell lines may be helpful in exploring this area.
